BetterLife Pharma (BETRF) Stock Price, News & Analysis

Company Overview

BetterLife Pharma (OTCMKTS:BETRF) is a life sciences company specializing in the development, manufacture and distribution of health and wellness products. The company’s core business activities include nutraceutical research, formulation of dietary supplements and production of personal care solutions. BetterLife Pharma positions itself at the intersection of modern science and traditional wellness, focusing on natural ingredients and evidence-based formulations aimed at supporting immune health, cognitive function and overall vitality.

Through a diversified product portfolio, BetterLife Pharma offers vitamins, minerals and botanical extracts designed to meet the needs of a broad consumer base. The company has expanded into advanced topical formulations, including anti-aging serums and therapeutic skincare lines. It also markets a range of specialty products targeting inflammation relief, metabolic support and stress management, leveraging proprietary extraction techniques to enhance bioavailability and efficacy.

Founded in 2018 and headquartered in Vancouver, Canada, BetterLife Pharma has grown its global footprint by establishing strategic partnerships across North America, Europe and Asia Pacific. The company distributes its products through an omni-channel approach that includes direct-to-consumer e-commerce platforms, third-party online retailers and select retail pharmacy chains. This multi-channel model enables BetterLife Pharma to reach health-conscious consumers in over 20 countries, while maintaining flexible supply chain operations and quality control standards in its ISO-certified manufacturing facilities.

BetterLife Pharma’s leadership team is led by CEO Alexander Orenstein, who brings over 15 years of experience in the nutraceutical industry and a background in pharmaceutical research. The senior management team also includes Chief Scientific Officer Dr. Maya Patel, responsible for overseeing the company’s R&D initiatives, and CFO Claire Zhang, who manages financial strategy and investor relations. Under their guidance, BetterLife Pharma continues to invest in clinical studies and strategic collaborations aimed at expanding its pipeline of innovative wellness solutions.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.06 to $0.09
• 52-Week Range: $0.05 to $0.14
• Volume: 1,340 shs
• Average Volume: 22,611 shs
• Market Capitalization: $8.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BetterLife Pharma Stock Analysis - MarketRank™

BetterLife Pharma scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BetterLife Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BetterLife Pharma is -6.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BetterLife Pharma is -6.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of BetterLife Pharma has been sold short.

Short Interest Ratio / Days to Cover

BetterLife Pharma has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BetterLife Pharma has recently increased by 10.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BetterLife Pharma does not currently pay a dividend.

Dividend Growth

BetterLife Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.08% of the float of BetterLife Pharma has been sold short.

Short Interest Ratio / Days to Cover

BetterLife Pharma has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BetterLife Pharma has recently increased by 10.19%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BetterLife Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BetterLife Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.77% of the stock of BetterLife Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.01% of the stock of BetterLife Pharma is held by institutions.

BETRF Stock Analysis - Frequently Asked Questions

How have BETRF shares performed this year?

BetterLife Pharma's stock was trading at $0.0720 at the start of the year. Since then, BETRF stock has decreased by 5.0% and is now trading at $0.0684.

How do I buy shares of BetterLife Pharma?

Shares of BETRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/14/2025
• Next Earnings (Estimated): 9/23/2025
• Fiscal Year End: 1/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BETRF
• CIK: 1464165
• Web: www.abetterlifepharma.com
• Phone: 604-221-0595
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.55 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -609.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.04
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -1.71

Miscellaneous

• Outstanding Shares: 129,463,000
• Free Float: 99,045,000
• Market Cap: $8.86 million
• Optionable: Not Optionable
• Beta: 1.45